根据最新披露,InMed Pharmaceuticals Inc(InMed Pharmaceuticals Inc)在完成相关交易后,合并公司的备考股权价值预计将达到约4.214亿美元。这一估值已将同时进行的私募配售所得资金纳入计算。
根据最新披露,InMed Pharmaceuticals Inc(InMed Pharmaceuticals Inc)在完成相关交易后,合并公司的备考股权价值预计将达到约4.214亿美元。这一估值已将同时进行的私募配售所得资金纳入计算。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.